Holly Jennings, MD
Internal Medicine · Fort Smith, ARNPI 1083602825
Payments from drug & device makers
Across 176 payments — averaging $18.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$533
- Amgen$513
- Lilly USA, LLC$493
- Novo Nordisk$480
- AstraZeneca$160
- AbbVie$131
- plus $933 from 24 others
What the payments were for
- Food & beverage$3,243100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 33 | $533 |
| Amgen | 20 | $513 |
| Lilly USA, LLC | 27 | $493 |
| Novo Nordisk | 26 | $480 |
| AstraZeneca | 11 | $160 |
| AbbVie(2 entities) | 8 | $131 |
| Bayer | 6 | $89 |
| Otsuka America Pharmaceutical, Inc. | 4 | $86 |
| Johnson & Johnson | 4 | $76 |
| GSK | 5 | $76 |
| Daiichi Sankyo Inc. | 3 | $63 |
| Boehringer Ingelheim | 3 | $56 |
| Boston Scientific | 2 | $53 |
| Merck | 3 | $47 |
| Dexcom, Inc. | 2 | $46 |
| Xeris Pharmaceuticals, Inc. | 2 | $46 |
| Insulet Corporation | 2 | $43 |
| Abbott | 2 | $40 |
| Shield Therapeutics Inc | 2 | $32 |
| Acadia Pharmaceuticals Inc | 1 | $27 |
| Novartis | 1 | $21 |
| Abiomed | 1 | $21 |
| Cequr Corporation | 1 | $18 |
| Exact Sciences | 1 | $17 |
| Valeritas, Inc. | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $13 |
| Ironwood Pharmaceuticals, Inc | 1 | $13 |
| Cashflow Solutions, LLC | 1 | $12 |
| Corium, LLC | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,243 in reported general payments places this provider in the 85th percentile of 614 internal medicine providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 201 | $155,681 |
| JardianceEmpagliflozin | 86 | $86,494 |
| MounjaroTirzepatide | 25 | $42,802 |
| RybelsusSemaglutide | 29 | $40,908 |
| OzempicSemaglutide | 26 | $29,287 |
| XareltoRivaroxaban | 24 | $28,584 |
| Tresiba Flextouch U-100Insulin Degludec | 50 | $22,540 |
| LinzessLinaclotide | 17 | $18,998 |
| FarxigaDapagliflozin Propanediol | 12 | $11,388 |
| EntrestoSacubitril/Valsartan | 15 | $11,033 |
| SymbicortBudesonide/Formoterol Fumarate | 25 | $10,217 |
| Breo ElliptaFluticasone/Vilanterol | 16 | $7,773 |
| Atorvastatin Calcium | 587 | $5,067 |
| Potassium Chloride | 254 | $4,870 |
| Pantoprazole Sodium | 410 | $4,691 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $533 | $155,681201 claims |
| Boehringer IngelheimJardiance | $56 | $86,49486 claims |
| Novo NordiskRybelsus, Ozempic | $480 | $70,19555 claims |
| Lilly USA, LLCMounjaro | $493 | $42,80225 claims |
| Johnson & JohnsonXarelto | $76 | $28,58424 claims |
| AbbVieLinzess, Synthroid | $131 | $22,04554 claims |
| AstraZenecaFarxiga, Symbicort | $160 | $21,60637 claims |
| NovartisEntresto | $21 | $11,03315 claims |
| GSKBreo Ellipta | $76 | $7,77316 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 614 internal medicine providers in Arkansas.
Other internal medicine in Fort Smith
- Tyree SealsFort Smith$14K
- Hubert LandersFort Smith$7K
- Brent ReevesFort Smith$6K
- Beena SyedFort Smith$6K
- Kendall WagnerFort Smith$6K
- Sumer PhillipsFort Smith$6K
- Becky YarboroughFort Smith$6K
- Priyantha WijewardaneLittle Rock$43.6M
- Joseph RoseLittle Rock$1.1M
- David JohnsonSearcy$630K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.